Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 415-415
Open Access | Times Cited: 15

Showing 15 citing articles:

Drug resistance in human cancers — Mechanisms and implications
Sudikshaa Vijayakumar, Raveena Dhakshanamoorthy, Akshaya Baskaran, et al.
Life Sciences (2024) Vol. 352, pp. 122907-122907
Closed Access | Times Cited: 5
Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
Jing-Zan Zhang, Lin Zhang, Xin Ding, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117240-117240
Closed Access
Lactoferrin-Derived Peptide Chimera Induces Caspase-Independent Cell Death in Multiple Myeloma
Young‐Saeng Jang, Shima Barati Dehkohneh, Jaewon Lim, et al.
Cells (2025) Vol. 14, Iss. 3, pp. 217-217
Open Access
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
H. N. Abramson
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15674-15674
Open Access | Times Cited: 7
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 6, pp. 833-842
Open Access | Times Cited: 2
Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells
Kuntal Bhowmick, Max Von Suskil, Omar S. Al‐Odat, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33091-e33091
Open Access | Times Cited: 2
New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies
Romina A. Guedes, J. Grilo, Andreia Neves Carvalho, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1096-1096
Open Access | Times Cited: 3
t(11;14) status is stable between diagnosis and relapse, and concordant between detection methodologies based on fluorescence <i>in situ</i> hybridization and next-generation sequencing in patients with multiple myeloma
Hervé Avet‐Loiseau, Raphaële Thiébaut-Millot, Xiaotong Li, et al.
Haematologica (2023)
Open Access | Times Cited: 2
Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021
Kai Kysenius, Anna Anttalainen, Iiro Toppila, et al.
Annals of Hematology (2024) Vol. 103, Iss. 8, pp. 2931-2943
Open Access
Lactoferrin-Derived Peptide Chimera Induces Caspase-independent Cell Death in Multiple Myeloma
Young‐Saeng Jang, Shima Barati Dehkohneh, Jaewon Lim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Cytotoxic Effects of the Combination of Pam3CSK4 with Carfilzomib, Ixazomib, and Venetoclax in Human Multiple Myeloma Cells
Kübra Dilan Avcı, Müjgan Özdemir Erdoğan, Saliha Handan Yıldız, et al.
Molecular Biology (2024) Vol. 58, Iss. 6, pp. 1268-1279
Closed Access
A Study on Renal Failure Management in Patients Diagnosed With Multiple Myeloma
Lama M Almuhaysen, Amal Badr Abu Al Alaa
Cureus (2023)
Open Access | Times Cited: 1
Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study
Lalit Kumar, Sameer Melinkeri, Prasanth Ganesan, et al.
Future Oncology (2023) Vol. 20, Iss. 4, pp. 191-205
Open Access | Times Cited: 1
The poignant paradox of treating multiple myeloma in young patients
Suvir Singh, Kaveri Joshi
Cancer Research Statistics and Treatment (2023) Vol. 6, Iss. 4, pp. 611-612
Open Access
Diallyl disulfide synergizes with melphalan to increase apoptosis and DNA damage through elevation of reactive oxygen species in multiple myeloma cells
Wei Hu, Jingqi Sun, Yanyan Zhang, et al.
Annals of Hematology (2023) Vol. 103, Iss. 4, pp. 1293-1303
Closed Access
Page 1

Scroll to top